HealthDay News — The data support continued access to tecovirimat for treatment of monkeypox virus infection, with subjective improvement seen at a median of 3 days after initiation of treatment, according to research published in the September 9 early-release issue of the US Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Noting that use of tecovirimat for treatment of monkeypox in the US is permitted only through a US Food and Drug Administration-regulated Expanded Access Investigational New Drug mechanism, Kevin O’Laughlin, MD, from the CDC Monkeypox Emergency Response Team, and colleagues describe the characteristics of persons treated with tecovirimat for monkeypox virus infection.

Intake and outcome forms were available for 549 and 369 patients, respectively, as of August 20, 2022. The researchers found that 97.7% of the patients were men (median age, 36.5 years) and 38.8% were non-Hispanic White. Overall, 99.8% of patients were prescribed oral tecovirimat, and 93.1% were not hospitalized. Of the patients with monkeypox virus infection who received tecovirimat, about half were living with HIV infection. The median interval was three days from initiation of tecovirimat to subjective improvement, with no difference by HIV infection status. In 3.5% of patients, adverse events were reported; all but one were nonserious.

“Currently, there are no human data demonstrating the efficacy of tecovirimat, and clinical trials are necessary to elucidate clinical efficacy in patients with monkeypox virus infection, indications for treatment, and ideal duration of treatment,” the authors write.

Abstract/Full Text